Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Science
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
-
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
-
Calithera Biosciences Appoints Scott Garland to Board of Directors
-
Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Science
